Search
Retinal_Health_DR infographic.pdf
Retinal_Health_Flyer_BIO-2021_bis-2021-08-03.pdf
Making More Health at a Glance.pdf
Partnering in Retinal Health MAY 2024 CORP.pdf
Partnering in Mental Health Disorders MAY 2024 CORP _0.pdf
Making More Health - CREATE - Magazine Social Entrepreneurship - Edition 2023
Partnering Interests in Retinal Health
partnering-retinal-health-may-2023-corp.pdf
BI-access-to-healthcare-strategy
public health
BI_Animal_Health.pdf
190326_BI_Beethoven_Infographic_Animal-Human-Health_Final.pdf
190326_BI_Beethoven_Infographic_Animal-Human-Health_Final.pdf
Boehringer Ingelheim Animal Health Business Unit Factsheet_2.pdf
Cat Health Booklet.pdf
ForBetterHealth.pdf
Nerandomilast (BI 1015550)
Nerandomilast (BI 1015550): PDE4B inhibitor
Approval for Aservo EquiHaler equine asthma therapy
Boehringer Ingelheim receives approval for Aservo® EquiHaler®, industry first equine asthma therapy
GARC Louis Nel interview on global rabies control
GARC’s Executive Director Professor Louis Nel shares what it takes to fight rabies.
sustainably fighting rabies info hub
Did you know that every nine minutes, rabies takes a human life? Find out how we support the elimination of this deadly disease.
Launch of first veterinary vaccines produced in China
Swine vaccine Ingelvac PRRS MLV, produced by Boheringer Ingelheim veterinary vaccine manufacturing plant in Taizhou is now officially supplied to the China market.
Boehringer Ingelheim strong growth pipeline acceleration 2023
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Nerandomilast (BI 1015550)
Nerandomilast (BI 1015550): PDE4B inhibitor
Arti-cell Forte stem cell-based veterinary product
Boehringer Ingelheim launches the first-ever registered stem cell-based veterinary medicine